Abstract | PURPOSE: PATIENTS AND METHODS: This was a case-control cohort study of 103 consecutive patients with Child-Pugh class A who had a large (>10 cm) HCC with PVT. The patients were assigned to receive either combined transarterial epirubicin (50 mg/m(2)) plus cisplatin (60 mg/m(2)) chemo-lipiodolization and systemic 5-fluorouracil (200 mg/m(2)) chemo-infusion ( ECF regimen) at monthly intervals (n=80) or conservative management (n=23). RESULTS: The objective tumor response (21.3 vs. 0%, P=0.011) and overall survival (8.7 vs. 3.5 months, P<0.001) were significantly better in the treatment group than in the conservative group. The prognostic factors for survival were tumor type (P=0.007), bilobar involvement (P=0.001), distant metastasis (P=0.009) and objective tumor response (P<0.001) for the treatment group. Survival benefits with the treatment were also maintained in each subgroup after stratification of these variables. CONCLUSIONS: This study suggests that when the hepatic function is preserved, a therapeutic strategy could be more beneficial than conservative management for such a large extensive HCC. As a therapeutic option, a combination therapy using ECF regimen may provide a significantly better tumor response and survival benefit in patients with large HCC invading the portal vein.
|
Authors | Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Hyun Jong Oh, Min Soo Kim, So Yeon Lee, Chang Wook Kim, U Im Chang, Soon Woo Nam, Sang Bok Cha, Young Joon Lee, Ho Jong Chun, Byung Gil Choi, Jae Young Byun, Seung Kew Yoon |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 59
Issue 1
Pg. 9-15
(Jan 2007)
ISSN: 0344-5704 [Print] Germany |
PMID | 16614848
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antimetabolites, Antineoplastic
- Antineoplastic Agents
- Epirubicin
- Cisplatin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antibiotics, Antineoplastic
(administration & dosage)
- Antimetabolites, Antineoplastic
(administration & dosage)
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Carcinoma, Hepatocellular
(drug therapy, pathology)
- Case-Control Studies
- Cause of Death
- Cisplatin
(administration & dosage)
- Epirubicin
(administration & dosage)
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Infusions, Intra-Arterial
- Liver Diseases
(drug therapy)
- Liver Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Portal Vein
(pathology)
- Prognosis
- Survival Analysis
- Tomography, X-Ray Computed
- Treatment Outcome
- Venous Thrombosis
(pathology)
|